- Research article
- Open Access
Next Generation Sequencing identifies mutations in GNPTG gene as a cause of familial form of scleroderma-like disease
© The Author(s). 2017
Received: 20 July 2017
Accepted: 18 September 2017
Published: 26 September 2017
Scleroderma is a multisystem disease, characterized by fibrosis of skin and internal organs, immune dysregulation, and vasculopathy. The etiology of the disease remains unknown, but it is likely multifactorial. However, the genetic basis for this condition is defined by multiple genes that have only modest effect on disease susceptibility.
Three Moroccan siblings, born from non-consanguineous Moroccan healthy parents were referred for genetic evaluation of familial scleroderma. Whole Exome Sequencing was performed in the proband and his parents, in addition to Sanger sequencing that was carried out to confirm the results obtained.
Mutation analysis showed two compound heterozygous mutations c.196C>T in exon 4 and c.635_636delTT in exon 9 of GNPTG gene. Sanger sequencing confirmed these mutations in the affected patient and demonstrated that their parents are heterozygous carriers.
Our findings expand the mutation spectrum of the GNPTG gene and extend the knowledge of the phenotype–genotype correlation of Mucolipidosis Type III gamma. This report also highlights the diagnostic utility of Next Generation Sequencing particularly when the clinical presentation did not point to specific genes.
Scleroderma is a complex disease characterized by vascular involvement and progressive sclerosis of the skin and other organs. Its etiology is still unknown but it is likely multifactorial. The importance of the genetic contribution in this disease is still not completely understood. However, numerous papers were raised in this issue. Thus an increased chromosomal breakage was described with systemic scleroderma and segregated as a dominant marker . Also, several genome-wide association studies disclosed multiple loci linked to increased risk of scleroderma .
In recent years, the use of massive parallel sequencing, or Next Generation Sequencing (NGS), is revolutionizing genetic investigation as well as clinical practice, mostly when dealing with rare diseases. The low cost of sequencing and growing bioinformatic capacity will permit the routine clinical use of these tools in the rapid diagnosis of Mendelian disorders with heterogeneous phenotypes. NGS can be used in several ways: as a panel targeting selected genes, as a test sequencing the coding regions of the genome (Whole Exome Sequencing/WES), or as an exam where the whole genome, with its coding and non-coding regions, is sequenced. This technology is also rapidly expanding into the genetic diagnostics field, expected to soon replace the standard Sanger sequencing. Recently, this approach allowed identification of novel gene variants and pathways that may contribute to scleroderma risk and/or severity .
Here we describe three Moroccan sibling presenting a familial form of scleroderma-like, and we highlight the crucial performance of WES in diagnosis issues.
Whole Exome Sequencing
Whole Exome Sequencing (WES) was carried out in the proband (III-2) and his parents (II-3, II-4). In addition, Sanger sequencing was performed both in the parents and in the three affected siblings to confirm the results obtained. Genomic DNA was extracted from peripheral blood samples using the salting-out method. 500 ng of fragmented DNA (enzymatic fragmentation, Kapa Hyper Plus Kit) was amplified in compliance with user guide, and was subjected to enrichment with SeqCap EZ Human Exome v3.0 (Roche Nimblegen). The 64 enriched megabases were sequenced using an Illumina HiSeq 2500 system in rapid run paired-end mode (2x100bp). Raw data (bcl files) were converted in fastq files using bcl2fastq v1.8.4 (Illumina).
The sequence reads were aligned with the human genome reference sequence (University of California Santa Cruz, human genome assembly 19 (UCSC hg19)) recommended by GATK best practices: mapping was performed using BWA-MEM, variant calling using GATK (haplotypecaller). Annotation and filtering steps were performed using VariantStudio (Illumina). We first removed non exonic variants and variants indicated as synonymous, Variants files of parents and index case were confronted: only variants that fulfilled recessive inheritance pattern were selected. Among them, variants with allele frequencies above 1% in ESP6500 exome project. All variants predicted to be benign were removed from the list of variants. Amino acid conservation across different species was studies using the UCSC Genome Browser.
Candidate gene sequencing
The putative mutation were validated via Sanger, sequencing the DNA of 5 family members with the following primers: F_ex4: 5′-GAAAACTGGTCCTTTGAAAACAG-3′; R_ex4: 5′-CCTGCACTCACGTGGACTC-3′ primer pair in exon 4 and F_ex8: 5′-CTGCATCCTCCACCTTCAG-3′; R_ex8: 5′-ACCTTCCTGCAGTTTTCCAG-3 primer pair in exon 9 of GNPTG gene. Sequencing was performed using BigDye Terminator v3.1 cycle sequencing, and the obtained sequences were analyzed on an ABI 3130 DNA Analyzer (Applied Biosystems).
Molecular genetic and bioinformatic analysis
Sanger sequencing confirmed these mutations in compound heterozygous state in the affected subjects (III-4, III-5). The parents were heterozygous carriers. The father carries the mutation c.635_636delTT and the mother carries the mutation c.196C>T, showing cosegregation of these mutations with the disease phenotype.
Activity of acid hydrolases in our patient compared to normal values
Activities in affected patients
Range of normal values
Mucolipidosis type III (ML III, MIM 252605), known as pseudo-Hurler polydystrophy, is an autosomal recessive disease caused by deficiency of UDP-N-acetylglucosamine 1-phosphotransferase . This enzyme is requested during the labeling of the acid hydrolases (AH) by the mannose-6-phosphate (M6P) in the cis Golgi cisterns . Only tagged AH are binded to M6P-receptors in the trans-Golgi and then delivered to the lysosome.The lack of M6P result in impaired targeting of hydrolases to lysosome, leading to their excessive release into the extracellular compartment . As a consequence, cells accumulate undigested macromolecules in their endosomes/lysosomes . Clinically, ML III is milder than other forms of mucolipidosis; this begins often from 3 years with slow coarsening of the facial features, growth deficiency, progressive joint stiffness, claw hand deformity, gait impairment with hip disease, scoliosis, dysostosis multiplex, normal intelligence or mild intellectual disability [8, 9]. Laboratory diagnosis is readily made by demonstrating increased lysosomal enzyme levels in serum, and reduced levels in extracts of cultured fibroblasts . Clinical presentation of the ML III is heterogeneous , and constitutes a challenge area with different diagnosis. Thereby, ML III α/β and ML III γ are almost indiscernible Clinically . Rheumatologic disorders, such as juvenile idiopathic rheumatoid arthritis, progressive pseudorheumatoid arthritis of childhood and scleroderma, are usually suspected in individuals with ML III [13, 14]. Our proband exhibited notably dermatological and rheumatological manifestations mimicking scleroderma. He had retracted, hard, tight and dry skin, Raynaud’s syndrome, hyper- and hypopigmentation areas. However, these alterations were seldom noted in individuals with ML III . Skin biopsy in these patients revealed increased cytoplasmic lysosomal granules or inclusions in lymphocytes and fibroblasts in various tissues. This histopathologic finding is known as I-cell phenotype , and was not obvious in our family. In addition, our patient had rheumatological manifestations mainly joint stiffness, elbows flexum, tendon retraction (wrist, MCP and PIP joints), limitation of hip abduction/rotation, limping gait, genu valgum, and kyphosis. Other finding were bilateral osteonecrosis of the femur, bone demineralization and joint space narrowing over the hand. Joint manifestations have been described in 46% to 97% of patients with scleroderma , predominantly at the hand joints, in particular the MCP and PIP joints [18, 19]. Radiological signs were mostly joint space narrowing, bone demineralisation, acro-osteolysis, flexion contracture, and calcinosis . However, bone necrosis has been rarely associated with scleroderma ; This was considered as a common complication of steroid therapy, and microvascular involvement as well [21, 22].
In this paper, due to clinical heterogeneous presentation of the disorder as well as recurrence in sibling, we opted for the WES which allowed to maintain the right diagnosis and exclude other differential ones. By that, two compound heterozygous mutations causing ML III gamma in Moroccan family were identified in the GNPTG gene, including a maternally inherited nonsense mutation c.196C>T (p.Arg66Ter), and a paternally inherited deletion mutation c.635_636delTT (p.Phe213Ter), in all three patients. The first variant is a single nucleotide substitution located in exon 4, described once as a pathogenic mutation that is predicted to severely damage the protein product . The second mutation is a small deletion c.635_636delTT (p.Phe213Ter) located in exon 9, this variant was reported in heterozygous state in healthy people, but never seen in affected individuals, making it a new pathogenic mutation related to mucolipidosis. Based on UCSC server (Fig. 3), these mutations lies within a conserved domain. To the best of our knowledge, 24 different mutations in the GNPTG gene have been reported, including six missense/nonsense mutations, seven small deletions, four small insertions, two gross deletions and five splice site mutations [http://www.hgmd.cf.ac.uk/ac/gene.php?gene=GNPTG]. However, no GNPTG mutations have been reported in the Moroccan population yet.
We describe here a Moroccan family with ML III mimicking scleroderma, thus we highlight the crucial interest of WES to straighten the suitable diagnosis among several suspicions. We see herein how the analysis of three individuals from a single family helped to narrow the list of candidate mutations, and delineate the disease gene using a standard clinical assay.
We are grateful for the cooperation of the patient’s family.
This study received no direct funding.
Availability of data and materials
Please contact author for data requests.
AZ: Drafted the manuscrit and carried out the Sanger and NGS analysis. SA: Drafted the manuscrit. JL: Corresponding author, participated of the design of the study and in the NGS analysis. HE: Provided clinical data. BC: Provided clinical data and health care of patient. LR: NGS platforme and raw data generation. GE: NGS platforme and raw data generation. MT: NGS platforme and raw data generation. SE: NGS platforme and raw data generation. AS: Design of the study. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This work was not submitted as a research project. Thus, we proceed only for a written consent that is common in our laboratory. Ethical approval for this study is deemed according to national regulations.
Consent for publication
No identifiable data is included in the paper.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Rittner G, Schwanitz G, Baur MP, Black CM, Welsh KI, Kuhnl P, Rittner C. Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet. 1988;81:64–70.View ArticlePubMedGoogle Scholar
- Korman BD, Criswell LA. Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance. Curr Rheumatol Rep. 2015;17:21.View ArticlePubMedPubMed CentralGoogle Scholar
- Mak AC, Tang PL, Cleveland C, Smith MH, Connolly MK, Katsumoto TR, Wolters PJ, Kwok PY, Criswell LA. Whole Exome Sequencing for identification of potential causal variants for diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2016;68:2257–62.View ArticlePubMedPubMed CentralGoogle Scholar
- Tappino B, Chuzhanova NA, Regis S, Dardis A, Corsolini F, Stroppiano M, Tonoli E, Beccari T, Rosano C, Mucha J, Blanco M, Szlago M, Di Rocco M, Cooper DN, Filocamo M. Molecular characterization of 22 novel UDP-N-acetylglucosamine-1-phosphate transferase alpha- and beta-subunit (GNPTAB) gene mutations causing mucolipidosis types IIalpha/beta and IIIalpha/beta in 46 patients. Hum Mutat. 2009;30:E956–73.View ArticlePubMedGoogle Scholar
- Coutinho MF, Prata MJ, Alves S. Mannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunction. Mol Genet Metab. 2012;105:542–50.View ArticlePubMedGoogle Scholar
- Kollmann K, Pohl S, Marschner K, Encarnacao M, Sakwa I, Tiede S, Poorthuis BJ, Lubke T, Muller-Loennies S, Storch S, Braulke T. Mannose phosphorylation in health and disease. Eur J Cell Biol. 2010;89:117–23.View ArticlePubMedGoogle Scholar
- Ludwig T, Munier-Lehmann H, Bauer U, Hollinshead M, Ovitt C, Lobel P, Hoflack B. Differential sorting of lysosomal enzymes in mannose 6-phosphate receptor-deficient fibroblasts. EMBO J. 1994;13:3430–7.PubMedPubMed CentralGoogle Scholar
- Kelly TE, Thomas GH, Taylor HA Jr, McKusick VA, Sly WS, Glaser JH, Robinow M, Luzzatti L, Espiritu C, Feingold M, Bull MJ, Ashenhurst EM, Ives EJ. Mucolipidosis III (pseudo-Hurler polydystrophy): Clinical and laboratory studies in a series of 12 patients. Johns Hopkins Med J. 1975;137:156–75.PubMedGoogle Scholar
- Cury GK, Matte U, Artigalas O, Alegra T, Velho RV, Sperb F, Burin MG, Ribeiro EM, Lourenco CM, Kim CA, Valadares ER, Galera MF, Acosta AX, Schwartz IV. Mucolipidosis II and III alpha/beta in Brazil: analysis of the GNPTAB gene. Gene. 2013;524:59–64.View ArticlePubMedGoogle Scholar
- Song J, Lee DS, Cho HI, Kim JQ, Cho TJ. Biochemical characteristics of a Korean patient with mucolipidosis III (pseudo-Hurler polydystrophy). J Korean Med Sci. 2003;18:722–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Tylki-Szymanska A, Czartoryska B, Groener JE, Lugowska A. Clinical variability in mucolipidosis III (pseudo-Hurler polydystrophy). Am J Med Genet. 2002;108:214–8.View ArticlePubMedGoogle Scholar
- Liu S, Zhang W, Shi H, Meng Y, Qiu Z. Three novel homozygous mutations in the GNPTG gene that cause mucolipidosis type III gamma. Gene. 2014;535:294–8.View ArticlePubMedGoogle Scholar
- KASAPKARA ÇS, AKÇABOY M, EROĞLU FK, DERİNKUYU BE. Mucolipidosis Type III: A Rare Disease in Differential Diagnosis of Joint Stiffness in Pediatric Rheumatology. Arch Rheumatol. 2018;33:i–vi.Google Scholar
- Pantoja Zarza L, Diez Morrondo C. Skeletal deformities in mucolipidosis III. Reumatologia Clinica. 2014;10:340–1.View ArticlePubMedGoogle Scholar
- Herd JK, Dvorak AD, Wiltse HE, Eisen JD, Kress BC, Miller AL. Mucolipidosis type III. Multiple elevated serum and urine enzyme activities. Am J Dis Child. 1978;132:1181–6.View ArticlePubMedGoogle Scholar
- Kerr DA, Memoli VA, Cathey SS, Harris BT. Mucolipidosis type III alpha/beta: the first characterization of this rare disease by autopsy. Arch Pathol Lab Med. 2011;135:503–10.PubMedPubMed CentralGoogle Scholar
- Avouac J, Guerini H, Wipff J, Assous N, Chevrot A, Kahan A, Allanore Y. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis. 2006;65:1088–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. Best Pract Res Clin Rheumatol. 2008;22:339–50.View ArticlePubMedGoogle Scholar
- Lorand V, Czirjak L, Minier T. Musculoskeletal involvement in systemic sclerosis. Presse Med. 2014;43:e315–28.View ArticlePubMedGoogle Scholar
- Cavallasca JA, Laborde HA, Araujo MB, Nasswetter GG. Multiple avascular necrosis in a patient with systemic lupus erythematosus/systemic sclerosis overlap syndrome. Clin Rheumatol. 2005;24:406–8.View ArticlePubMedGoogle Scholar
- Fossaluzza V, Peressini A, De Vita S. Multifocal ischemic necrosis of bone in scleroderma. Clin Rheumatol. 1991;10:95–7.View ArticlePubMedGoogle Scholar
- Bruni C, Guiducci S, Bellando-Randone S, Matucci-Cerinic M. Avascular bone necrosis: an underestimated complication of systemic sclerosis. Semin Arthritis Rheum. 2017;47:e3–5.View ArticlePubMedGoogle Scholar
- Raas-Rothschild A, Bargal R, Goldman O, Ben-Asher E, Groener JE, Toutain A, Stemmer E, Ben-Neriah Z, Flusser H, Beemer FA, Penttinen M, Olender T, Rein AJ, Bach G, Zeigler M. Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III. J Med Genet. 2004;41:e52.View ArticlePubMedPubMed CentralGoogle Scholar